FDA Approves Auvelity for Agitation in Alzheimer’s Dementia
The FDA authorized Auvelity as the first non-antipsychotic treatment for agitation symptoms in adults with Alzheimer’s disease dementia
Archive 
FDA Approves Expanded Access for Pancreatic Cancer Drug Daraxonrasib
The FDA has authorized expanded access use of the experimental drug daraxonrasib for patients with metastatic pancreatic cancer who have exhausted other treatments
NIH Awards $150,000 to Teams Innovating Nutrition Research in Autoimmune Disease
Fifteen scientific teams received $10,000 each from the NIH for innovative approaches linking diet and nutrition to autoimmune disease onset and management
Suspected Hantavirus Outbreak Kills Three on Cruise Ship Near Cape Verde
A hantavirus infection aboard the MV Hondius cruise ship has resulted in three deaths and multiple illnesses while authorities work to contain the outbreak
NIH Discovers Novel Opioid Providing Pain Relief With Lower Addiction Risk
NIH researchers identified a new opioid compound that offers strong pain relief without typical addictive or respiratory side effects, showing promise for safer pain…
NIH Trial Finds Team-Based Care Lowers Blood Pressure in Low-Income Patients
A scalable care model in federally qualified health centers significantly reduced systolic blood pressure among underserved Americans with hypertension
Dr. Jonathan M. Green Named CEO of NIH Clinical Center
Dr. Jonathan M. Green will lead the NIH Clinical Center, overseeing its operations and expansion starting May 2026
NIH Trial Finds No Outcome Difference Between IV Fluids in Pediatric Septic Shock
A major NIH-supported study compared balanced crystalloid fluid and 0.9% saline in children with septic shock and found no significant differences in death or…
Symptom-Based Opioid Dosing Reduces Hospital Stay for Newborns with NOWS
An NIH-funded trial found that treating neonatal opioid withdrawal syndrome with symptom-triggered opioid doses shortens medication use and hospital stays
Weekly Semaglutide Added to Therapy Cuts Heavy Drinking in Obese Patients
A clinical trial finds that weekly semaglutide combined with cognitive behavioral therapy significantly reduces heavy drinking days among patients with alcohol use disorder and…